Long-term follow-up results of a pilot phase II study of multidrug chemotherapy (MVP-CAB) in patients with advanced urothelial cancer

Japanese Journal of Clinical Oncology

Volumn 29, Issue 4, 1999, Pages 204-208

  Gohji, Kazuo ^a,b   Ono, Yoshiharu ^a   Takenaka, Atsushi ^a   Nomi, Masashi ^a   Okamoto, Masayuki ^a   Yuen, Keiji ^a   Fujii, Akio ^a  

^a HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Chemotherapy; Metastasis; Urothelial cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; MVP CAB PROTOCOL; MVP-CAB PROTOCOL; VINCRISTINE;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PILOT STUDY; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS; VINCRISTINE;

EID: 0033108843     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/29.4.204     Document Type: Article

References (20)

1. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403-7.
2. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73.
3. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-5.
4. Igawa M, Urakami S, Shiina H, Ishibe, T, Kadena H, Usui T. Long-term results with M-VAC for advanced urothelial cancer: high response rate and low survival in patients with a complete response. Br J Urol 1995;76:321-4.
5. Levine E, Raghavan D. MVAC for bladder cancer: time to move forward again. J Clin Oncol 1993;11:387-9.
6. Connor JP, Olsson CA, Benson MC, Rapoport F, Sawczuk IS. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern. Urology 1989;34:353-6.
7. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase II intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial cancer: a cooperative group study. J Clin Oncol 1997;15:2564-9.
8. Fujii A, Oka N, Miyazaki S, Higuchi A, Itoh N, Okamoto Y, et al. Combination chemotherapy with methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) for metastatic urothelial cancer. Nippon Hinyoukika Gakkai Zasshi 1991;82:932-9 (in Japanese).
9. Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, et al. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report. Jpn J Clin Oncol 1993;23:291-8.
10. Blum RH, Carter SK, Agre K. A clinical review of bleomycin - a new antineoplastic agent. Cancer 1973;31:903-14.
11. Pavone-Macaluso M, EORTC Genito-urinary Tract Co-operative Group A. Single-drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin. A phase II multicentric co-operative study. Eur Urol 1976;2:138-41.
12. Richards B, Newling D, Fossa S, Bastable JRG, Denis L, Jones WB, et al. Vincristine in advancer bladder cancer: a European Organization for Research on Treatment of Cancer (EORTC) phase II study. Cancer Treat Rep 1983;67:575-7.
13. Afuso H. Experimental study on the evaluating the effectiveness of sequential administration of chemotherapeutic agents in bladder cancer. Nippon Hinyoukika Gakkai Zasshi 1984;75:1244-51 (in Japanese).
14. Carter SK, Bakowski MT, Hellmann K. Anticancer drugs. In: Yagoda A, editor. Chemotherapy of Cancer. New York: Wiley 1977;39-66.
15. Yagoda A. Chemotherapy of metastatic bladder cancer. Cancer 1980;45:1879-88.
16. Van Oosterom AT, Akaza H, Hall R, Hirao Y, Jones WG, Mastumura Y, et al. Response criteria phase II/phase III invasive bladder cancer. In: Denis L, Niijima T, Prout G, Schroeder FH, editors. Developments in Bladder Cancer. New York: Alan R. Liss 1986;301-10.
17. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441-5.
18. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-70.
19. Seligman PA, Crawford ED. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst 1991;83:1582-4.
20. Vaughn DJ, Malkowicz SB, Zoltick B, Mick R, Ramchandani P, Holroyde C, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 1998;16:255-60.